Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q3 2025 · 10-Q
Revenue$14.18M$14.18M+714.6% vs Q3 2024 Net Income-$12.77M-$12.77MN/M vs Q3 2024 EPS Diluted-$0.04-$0.04N/M vs Q3 2024 Operating Income-$12,187,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$23,833,000N/M Margins · derivedOperating margin-85.9%+3572.5 pt vs Q3 2024
Net margin-90.0%+3632.6 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 6, 2025 · 37 d after period end